[H2 receptor antagonists in the therapy of peptic ulcer disease].
Today histamine-H2-receptor antagonists are the most intensively investigated drugs in the therapy of acid related diseases. They are characterized by a clear mechanism of action, a convenient application form, a high tolerability, a low incidence of side effects, and a large therapeutic window. The single nocturnal dosage regimen of H2-blockers follows the concept to reduce substantially night time acidity only, which is believed to play a decisive pathogenetic role in peptic ulcer disease, while during day time physiological acid secretion remains unaffected. The clinical efficacy of this application form has been well documented in the healing and symptomatic relief of acute peptic ulcers. However, about 30% of patients still suffer from ulcer pain after a 2 weeks treatment period. A more flexible dosage regimen, which is more adapted to the ulcer symptoms of the patient will probably lead to even better clinical results.
D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005745:Gastric Acidity Determination; D006635:Histamine H2 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy*; D012008:Recurrence; D013329:Structure-Activity Relationship
D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists
H2-Rezeptorantagonisten in der Therapie der peptischen Ulkuserkrankung.